Adults 18 to 70, any sex, with Psoriasis or Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mean Percentage Change in PASIPrimary· 16 weeks
The Psoriasis Area and Severity Index Score (PASI) is a physician assessment that combines the assessment of the severity of and area affected by psoriasis into a single score in the range 0 (no disease) to 72 (maximal disease).The efficacy of EDP1815 will be measured using the mean percentage change in PASI from baseline to week 16.
Group
Value
95% CI
All Placebo
-14.39
-22.66 – -5.52
Cohort 1 Active
-20.37
-31.65 – -9.47
Cohort 2 Active
-22.73
-33.08 – -11.88
Cohort 3 Active
-23.49
-34.18 – -12.12
Mean Percentage Change in PASISecondary· 12 weeks
The Psoriasis Area and Severity Index Score (PASI) is a physician assessment that combines the assessment of the severity of and area affected by psoriasis into a single score in the range 0 (no disease) to 72 (maximal disease). The efficacy of EDP1815 will be measured using the mean percentage change from baseline in PASI from baseline at weeks 4, 8, and 12.
Group
Value
95% CI
All Placebo
-19.24
-26.17 – -11.57
Cohort 1 Active
-21.84
-31.85 – -12.91
Cohort 2 Active
-22.57
-31.32 – -13.05
Cohort 3 Active
-19.13
-28.77 – -9.83
Mean Absolute Change in PASISecondary· 16 weeks
The Psoriasis Area and Severity Index Score (PASI) is a physician assessment that combines the assessment of the severity of and area affected by psoriasis into a single score in the range 0 (no disease) to 72 (maximal disease). The efficacy of EDP1815 will be measured using the mean absolute change from baseline in PASI from baseline at weeks 4, 8, 12, and 16.
Group
Value
95% CI
All Placebo
-1.16
-1.87 – -0.41
Cohort 1 Active
-1.85
-2.74 – -0.91
Cohort 2 Active
-1.88
-2.77 – -1.04
Cohort 3 Active
-1.97
-2.92 – -1.08
Achievement of PASI-50Secondary· 16 weeks
The efficacy of EDP1815 will be measured using the achievement of PASI-50 at weeks 4, 8, 12, and 16. PASI-50 is defined by at least a 50% reduction from baseline in the PASI score.
Group
Value
95% CI
All Placebo
8
Cohort 1 Active
11
Cohort 2 Active
15
Cohort 3 Active
10
Time to First Achievement of PASI-50Secondary· 20 weeks
The efficacy of EDP1815 will be measured using the time to first achievement of PASI-50
Group
Value
95% CI
All Placebo
160
160 – NA
Cohort 1 Active
NA
NA – NA
Cohort 2 Active
NA
NA – NA
Cohort 3 Active
146
146 – 154
Achievement of PASI-75Secondary· 16 weeks
The efficacy of EDP1815 will be measured using the achievement of PASI-75 at week 16. PASI-75 response is defined by at least a 75% reduction from baseline in the PASI score.
Group
Value
95% CI
All Placebo
2
Cohort 1 Active
2
Cohort 2 Active
4
Cohort 3 Active
4
Achievement of PASI-90Secondary· 16 weeks
The efficacy of EDP1815 will be measured using the achievement of PASI-90 at week 16.PASI-90 response is defined by at least a 90% reduction from baseline in the PASI score.
Group
Value
95% CI
All Placebo
0
Cohort 1 Active
2
Cohort 2 Active
2
Cohort 3 Active
0
Achievement of PASI-100Secondary· 16 weeks
The efficacy of EDP1815 will be measured using the achievement of PASI-100 at week 16. PASI-100 response is defined as achieving a complete resolution of all disease.
Group
Value
95% CI
All Placebo
0
Cohort 1 Active
0
Cohort 2 Active
0
Cohort 3 Active
0
Achievement of PGA of 0 or 1 With a ≥2-point Improvement From BaselineSecondary· 16 weeks
The efficacy of EDP1815 will be measured using the achievement of PGA of 0 or 1 with a ≥2-point improvement from baseline at Week 16 \[PGA = Physician's Global Assessment\]. The National Psoriasis Foundation Psoriasis Score version of a PGA is calculated by averaging the total body erythema, induration, and desquamation scores. Erythema, induration, and desquamation will be scored on a 6-point scale, ranging from 0 (clear) to 5 (severe): the total PGA score is defined as the average of the erythema, induration, and desquamation scores. PGA score of 0 or 1 is defined as clear or almost clear of
Group
Value
95% CI
All Placebo
4
Cohort 1 Active
4
Cohort 2 Active
5
Cohort 3 Active
5
Achievement of PGA of 0Secondary· 16 weeks
The efficacy of EDP1815 will be measured using the achievement of PGA of 0 at Week 16 \[PGA = Physician's Global Assessment\]. The National Psoriasis Foundation Psoriasis Score version of a PGA is calculated by averaging the total body erythema, induration, and desquamation scores. Erythema, induration, and desquamation will be scored on a 6-point scale, ranging from 0 (clear) to 5 (severe): the total PGA score is defined as the average of the erythema, induration, and desquamation scores. PGA score of 0 or 1 is defined as clear or almost clear of psoriasis. A PGA 0 is defined as clear or no s
Group
Value
95% CI
All Placebo
1
Cohort 1 Active
0
Cohort 2 Active
0
Cohort 3 Active
1
Mean Percentage Change in PGAxBSASecondary· 16 weeks
\[PGA = Physician's Global Assessment, BSA = Body Surface Area\]. The National Psoriasis Foundation Psoriasis Score version of a static Physicians Global Asessment (PGA) is calculated by averaging the total body erythema, induration, and desquamation scores. Erythema, induration, and desquamation will be scored on a 6-point scale, ranging from 0 (clear) to 5 (severe): the total PGA score is defined as the average of the erythema, induration, and desquamation scores.
Body surface area (BSA) measures the total area of the body affected by psoriasis. Psoriasis that occurs on less than 5 percent
Group
Value
95% CI
All Placebo
-0.05
-13.65 – 12.74
Cohort 1 Active
-9.13
-25.84 – 7.91
Cohort 2 Active
-3.04
-19.15 – 12.26
Cohort 3 Active
-17.16
-33.23 – -1.18
Mean Absolute Change in PGAxBSASecondary· 16 weeks
\[PGA = Physician's Global Assessment, BSA = Body Surface Area\]. The National Psoriasis Foundation Psoriasis Score version of a static Physicians Global Asessment (PGA) is calculated by averaging the total body erythema, induration, and desquamation scores. Erythema, induration, and desquamation will be scored on a 6-point scale, ranging from 0 (clear) to 5 (severe): the total PGA score is defined as the average of the erythema, induration, and desquamation scores.
Body surface area (BSA) measures the total area of the body affected by psoriasis. Psoriasis that occurs on less than 5 percent
Group
Value
95% CI
All Placebo
-0.01
-2.68 – 2.41
Cohort 1 Active
-2.67
-5.77 – 0.60
Cohort 2 Active
-0.84
-3.93 – 2.06
Cohort 3 Active
-3.54
-6.58 – -0.29
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event (AE) data were collected over a period of 20 weeks..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05682222 — Evaluation of the Immunopharmacology of EDP1815 and EDP2939
· Phase 1
· completed
NCT05439941 — A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials
· Phase 2
· terminated
NCT05121480 — A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
· Phase 2
· completed
NCT04488575 — Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection
· Phase 2
· terminated
NCT04393246 — mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms
· Phase 2, PHASE3
· completed
Other recruiting trials for Psoriasis
Currently open trials in the same condition.
NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria
· NA
· recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
· recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
· recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial
· Phase 2
· recruiting
NCT07250997 — PALLAS Laser for Skin Diseases
· NA
· recruiting
Other Evelo Biosciences, Inc. trials
Trials by the same sponsor.
NCT05682222 — Evaluation of the Immunopharmacology of EDP1815 and EDP2939
· Phase 1
· completed
NCT05439941 — A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials
· Phase 2
· terminated
NCT05121480 — A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
· Phase 2
· completed
NCT05066373 — Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms
· Phase 1
· completed
NCT04927195 — Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Evelo Biosciences, Inc.
Last refreshed: 19 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04603027.